Breaking News

Financial Report: Biogen Idec

By Kristin Brooks | January 29, 2014

Expanded MS franchise drives growth

Biogen Idec

4Q Revenues: $2.0 billion (+39%)

4Q Earnings: $457.3 million (+57%)

FY Revenues: $6.9 billion (+26%)

FY Earnings: $1.9 billion (+35%)

Comments: Growth in the quarter and FY were driven by sales of new multiple sclerosis drug, Tecfidera, with sales of $398 million in the quarter and $876 million for the year, and TYSABRI revenues, up 45% to $427 million in the quarter, and up 34% for the year to $1.5 billion, as a result of recording 100% of revenues after gaining full rights. AVONEX revenues were flat in the quarter at $751 million and up 3% for the year to $3.0 billion. Royalty revenues were $61 million in the quarter, up 9%, and $186 million for the year, up 10%.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks